PBT 0.00% 0.0¢ prana biotechnology limited

Biogen down 30%, aducanumab failed in AD, page-5

  1. 3,630 Posts.
    lightbulb Created with Sketch. 116
    OK, so Biogen have had about $20B so far wiped off their market cap because their AD candidate failed. Prana still has a couple of AD candidates and a PD program under way with a market cap of what, $20m. Brilliant move by management selling out just before the PD safety trial reports.
 
watchlist Created with Sketch. Add PBT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.